Choice A or Choice B?

The inaugural post at the Personalized Medicine Coalition's new blog discusses the interplay of personalized medicine and comparative effectiveness. Amy Miller at The Age of Personalized Medicine writes that if "done right, CER could do more to advance personalized medicine than any other policy under consideration right now" but if "done wrong" could set the field back. She says that the US Congress has before it two comparative effectiveness bills, one of each flavor. Miller says the Senate Finance Committee's version incorporates personalized medicine into its comparative effectiveness proposal while the Senate HELP bill and H.R. 3200 give funds to conduct existing comparative effectiveness programs.